Chris Freeman Sells 24,406 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) insider Chris Freeman sold 24,406 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $118.67, for a total value of $2,896,260.02. Following the sale, the insider directly owned 60,034 shares of the company’s stock, valued at $7,124,234.78. The trade was a 28.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Guardant Health Stock Up 6.4%

Shares of Guardant Health stock opened at $127.51 on Thursday. The stock has a market capitalization of $16.91 billion, a P/E ratio of -37.61 and a beta of 1.48. The stock has a 50 day moving average price of $93.34 and a two-hundred day moving average price of $99.48. Guardant Health, Inc. has a 12-month low of $37.73 and a 12-month high of $128.00.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GH. Canaccord Genuity Group upped their target price on Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Piper Sandler set a $127.00 target price on Guardant Health in a research report on Thursday, May 21st. Citigroup upped their target price on Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. JPMorgan Chase & Co. upped their target price on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. Nineteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $129.79.

Hedge Funds Weigh In On Guardant Health

Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Guardant Health by 2.1% during the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after purchasing an additional 251,939 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Guardant Health by 33.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after purchasing an additional 1,414,441 shares during the last quarter. Franklin Resources Inc. lifted its position in Guardant Health by 14.9% in the fourth quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock worth $343,348,000 after purchasing an additional 435,232 shares during the period. Geode Capital Management LLC lifted its position in Guardant Health by 9.4% in the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock worth $328,297,000 after purchasing an additional 277,001 shares during the period. Finally, Fuller & Thaler Asset Management Inc. lifted its position in Guardant Health by 3.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock worth $249,398,000 after purchasing an additional 72,162 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.